Cost-effectiveness of blood pressure lowering with a fixed combination of perindopril and indapamide in type 2 diabetes mellitus: A trial-based analysis using the advance study

Clarke, P. M., Glasziou, P., Alexander, J., Chalmers, J. and Patel, A. (2010). Cost-effectiveness of blood pressure lowering with a fixed combination of perindopril and indapamide in type 2 diabetes mellitus: A trial-based analysis using the advance study. In: ISPOR 4th Asia-Pacific Conference Research Abstracts. ISPOR 4th Asia-Pacific Conference, Phuket, Thailand, (A504-A504). 5-7 September 2010. doi:10.1111/j.1524-4733.2010.00793_2.x


Author Clarke, P. M.
Glasziou, P.
Alexander, J.
Chalmers, J.
Patel, A.
Title of paper Cost-effectiveness of blood pressure lowering with a fixed combination of perindopril and indapamide in type 2 diabetes mellitus: A trial-based analysis using the advance study
Conference name ISPOR 4th Asia-Pacific Conference
Conference location Phuket, Thailand
Conference dates 5-7 September 2010
Proceedings title ISPOR 4th Asia-Pacific Conference Research Abstracts   Check publisher's open access policy
Journal name Value in Health   Check publisher's open access policy
Place of Publication Hoboken, NJ, U.S.A.
Publisher Wiley-Blackwell Publishing
Publication Year 2010
Sub-type Published abstract
DOI 10.1111/j.1524-4733.2010.00793_2.x
ISSN 1098-3015
1524-4733
Volume 13
Issue 7
Start page A504
End page A504
Total pages 1
Language eng
Formatted Abstract/Summary
Objectives: To determine the cost-effectiveness of routine administration, irrespective of blood pressure, of a fi xed-dose combination of perindopril and indapamide to patients with Type 2 diabetes. METHODS: Prospective cost-effectiveness analysis within a 20 country randomized trial of 11,140 patients with Type 2 diabetes randomized to perindopril plus indapamide or placebo. We calculated cost per death averted at 4.3 years average follow-up and estimated cost per life-year gained by extrapolation.

Results: The ADVANCE trial showed a 14% relative risk reduction in all cause mortality (P < 0.03) and an 18% relative risk reduction (0.8% absolute reduction) in cardiovascular mortality (P < 0.03). Hospital admissions for coronary heart disease and coronary revascularization were reduced by 5%. Per patient perindopril-indapamide cost AUS$1368, but reduced total hospitalization costs by AUS$410 and other medication costs (mainly other blood pressure lowering drugs) by AUS$332. Quality of life, measured by the EQ-5D, was 0.80 (on a 0–1 scale); with no difference between groups. Absolute reduction in all-cause mortality was 1.1%, giving a cost per life saved of AUS$49,200, and life-time extrapolation estimated a cost per life-year saved of AUS$8,470 (discounted at 3%).

Conclusions:
The combination of perindopril and indapamide in patients with type 2 diabetes reduces all-cause mortality and appears cost-effective.

Q-Index Code EX
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Conference Paper
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Google Scholar Search Google Scholar
Created: Sun, 09 Jan 2011, 00:00:11 EST